Safety of Long-Term Propafenone Therapy for Cardiac Arrhythmia - Experience with 774 Patients
| Autor: | Philip J. Podrid, B S Beverly Novrit, Shmuel Ravid |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Drug
medicine.medical_specialty Side effect Physiology business.industry media_common.quotation_subject Cardiac arrhythmia Propafenone medicine.disease Pharmacotherapy Anesthesia Internal medicine Heart failure Toxicity medicine Cardiology Cardiology and Cardiovascular Medicine Adverse effect business media_common medicine.drug |
| Zdroj: | Journal of Electrophysiology. 1:580-590 |
| ISSN: | 0892-1059 |
| DOI: | 10.1111/j.1540-8167.1987.tb01451.x |
| Popis: | Long term propafenone therapy was initiated in 774 patients who were evaluated at 27 centers in the United States. The average duration of therapy was 183 days. During the treatment period, at least one toxic side effect occurred in 448 patients (58%). The most common reported adverse reactions were cardiovascular in 209 patients (27%), central nervous system in 160 patients (21%), and gastrointestinal in 159 patients (21%). Of those with cardiovascular side effects, 41 (5.3%) had aggravation of arrhythmia, 26 (3.4%) had the induction or worsening of congestive heart failure, and 65 (8.4%) had new conduction abnormalities. Although side effects were frequent, drug discontinuation due to the adverse reaction was necessary in only 114 patients (14.7%). The majority of side effects were dose related especially when 900 mg/day was administered. Additionally, the incidence of toxicity was directly related to age. We conclude that side effects are frequent during long-term propafenone therapy, but most are mild, dose related, and do not limit the use of the drug. Drug discontinuation because of an adverse reaction is only infrequently required. It is recommended that drug therapy begin with low doses (150 mg t.i.d) with careful and slow titration up to a maximum of 900 mg/day. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text